I

n a modest victory for Novartis, a Japanese court decided the drug maker and a former employee were not guilty of violating a law that bans fraudulent and exaggerated advertising claims in connection with a research paper about the Diovan heart drug. A Novartis spokesman confirmed the ruling.

The decision stems from an episode in 2014 when the company was accused of altering data in a study in order to make the drug appear better than rival medicines. The research was conducted by several Japanese universities, some of which determined results were falsified.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.